19 citations,
March 2018 in “Expert Opinion on Drug Safety” Most treatments for spondyloarthritis are safe, but monitoring and careful selection based on patient risks are important.
A girl with Crohn's disease developed hair loss due to her increased medication, a rare side effect seen in some children.
8 citations,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
12 citations,
May 2020 in “Dermatology and therapy” A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.
4 citations,
June 2013 in “The Journal of Rheumatology” The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.
3 citations,
February 2019 in “Disease Markers” The index to ring finger ratio may indicate disease severity in female ankylosing spondylitis patients, but not in males.
People with psoriasis have more health problems, including autoimmune diseases, than those without it.
April 2012 in “Journal of the American Academy of Dermatology” Psoriasis patients have more comorbidities, including autoimmune diseases and other health issues, than those without psoriasis.
Psoriasis is linked to a higher risk of autoimmune diseases and other health conditions.
12 citations,
March 2023 in “Frontiers in immunology” Atopic dermatitis increases the risk of some autoimmune diseases.
104 citations,
August 2008 in “Clinics in Dermatology” Treating psoriasis on the scalp, nails, and skin folds is challenging, often requiring systemic treatments for severe cases, with some success in topical and biologic treatments.
19 citations,
November 2016 in “Dermatology and therapy” Stopping the medication infliximab and starting new treatments helped a woman's hair grow back and improved her scalp condition.
23 citations,
July 2021 in “Advances in Therapy” Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.
1 citations,
August 2023 in “Acta dermato-venereologica” Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.
1 citations,
May 2023 in “Prospects in Pharmaceutical Sciences” New cytokine-targeted therapies show promise for treating alopecia areata.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine successfully treated a man's ashy dermatosis, clearing his skin lesions.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
1 citations,
September 2023 in “Dermatology and therapy” More research is needed to find the best treatment for dissecting cellulitis of the scalp.
1 citations,
October 2018 in “InTech eBooks” Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
May 2024 in “Journal of Education, Health and Sport” Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.
April 2018 in “Journal of Ayurveda and integrative medicine” Ayurvedic treatment improved hair growth in a person with hair loss.
2 citations,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
2 citations,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
6 citations,
July 2022 in “Journal of health economics and outcomes research” Adolescents with severe alopecia incur significantly higher healthcare costs.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
3 citations,
May 2018 in “Experimental Dermatology” Young HS patients often have other physical and mental health issues, and research on HS covers a wide range of topics including genetics, triggers, treatments, and the need for more data.
281 citations,
January 2013 in “British Journal of Dermatology” Manage vitiligo with treatments, address emotions, and use camouflage techniques.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.